Els Wagenaar

发表

Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites

Tom F. A. de Greef, Jos H. Beijnen, Luc Brunsveld, 2014, Molecular Pharmacology.

Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein

Piet Borst, J. Beijnen, P. Borst, 1996, British journal of pharmacology.

P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib

Jos H Beijnen, J. Beijnen, A. Schinkel, 2012, Journal of Pharmacology and Experimental Therapeutics.

The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk

T. Dale, A. Schinkel, J. Jonker, 2005, Nature Medicine.

The Drosophila homology of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless

Detlef Weigel, Paul Parren, Marcus Schuermann, 1987, Cell.

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2010, Molecular Cancer Therapeutics.

The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin

A. V. van Herwaarden, A. Schinkel, J. Jonker, 2005, Molecular Pharmacology.

P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2007, Antimicrobial Agents and Chemotherapy.

Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine

Alfred H. Schinkel, P. Pávek, A. Schinkel, 2005, Journal of Pharmacology and Experimental Therapeutics.

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

A. V. van Herwaarden, A. Schinkel, J. Jonker, 2006, Carcinogenesis.

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Ji-Ying Song, Jos H Beijnen, H. Rosing, 2007, The Journal of clinical investigation.

TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2)

A. Schinkel, J. Jonker, E. Wagenaar, 2005, Drug Metabolism and Disposition.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2003, Cancer research.

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

Jos H Beijnen, J. Beijnen, A. Schinkel, 2011, Drug Metabolism and Disposition.